KRAS G12C clinical trials at UCSF
3 research studies open to eligible people
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
open to eligible people ages 18 years and up
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
San Francisco, California and other locations
BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
open to eligible people ages 18 years and up
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
San Francisco, California and other locations
FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
open to eligible people ages 18 years and up
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
San Francisco, California and other locations
Our lead scientists for KRAS G12C research studies include Pamela Munster Michael Cheng.
Last updated: